- 1 **Title**: Protocol for a sequential, prospective meta-analysis to describe coronavirus disease
- 2 2019 (COVID-19) in the pregnancy and postpartum periods

3

- 4 Emily R. Smith<sup>1</sup>, Erin Oakley<sup>1</sup>, Siran He<sup>1</sup>, Rebecca Zavala<sup>1</sup>, Kacey Ferguson<sup>1</sup>, Lior Miller<sup>1</sup>, Gargi
- Wable Grandner<sup>1</sup>, Ibukun-Oluwa Omolade Abejirinde<sup>2</sup>, Yalda Afshar<sup>3</sup>, Homa Ahmadzia<sup>4</sup>, Grace
- 6 Aldrovandi<sup>5</sup>, Victor Akelo<sup>6</sup>, Beth A. Tippett Barr<sup>6</sup>, Elisa Bevilacqua<sup>7</sup>, Justin S. Brandt<sup>8</sup>, Natalie
- 7 Broutet<sup>2</sup>, Irene Fernández-Buhigas<sup>9, 10</sup>, Jorge Carrillo<sup>11</sup>, Rebecca Clifton<sup>12</sup>, Jeanne Conry<sup>13</sup>,
- 8 Erich Cosmi<sup>14</sup>, Camille Delgado-López<sup>15</sup>, Hema Divakar<sup>16</sup>, Amanda J. Driscoll<sup>17</sup>, Guillaume
- 9 Favre<sup>18</sup>, Valerie Flaherman<sup>19</sup>, Christopher Gale<sup>20</sup>, Maria M. Gil<sup>9, 10</sup>, Christine Godwin<sup>2, 21</sup>, Sami
- Gottlieb<sup>2</sup>, Olivia Hernandez Bellolio<sup>22</sup>, Edna Kara<sup>2</sup>, Sammy Khagayi<sup>23</sup>, Caron Rahn Kim<sup>2</sup>, Marian
- 11 Knight<sup>24</sup>, Karen Kotloff<sup>17, 29</sup>, Antonio Lanzone<sup>25, 26</sup>, Kirsty Le Doare<sup>27, 28</sup>, Christoph Lees<sup>29</sup>, Ethan
- Litman<sup>4</sup>, Erica M. Lokken<sup>30, 31</sup>, Valentina Laurita Longo<sup>26</sup>, Laura A. Magee<sup>32, 33</sup>, Raigam Jafet
- 13 Martinez-Portilla<sup>34, 35</sup>, Elizabeth McClure<sup>36</sup>, Torri D. Metz<sup>37</sup>, Deborah Money<sup>38</sup>, Edward Mullins<sup>29</sup>,
- Jean B. Nachega<sup>39, 40, 41</sup>, Alice Panchaud<sup>42, 43</sup>, Rebecca Playle<sup>44</sup>, Liona C. Poon<sup>45</sup>, Daniel
- Raiten<sup>46</sup>, Lesley Regan<sup>47</sup>, Gordon Rukundo<sup>48</sup>, Jose Sanin-Blair<sup>49</sup>, Marleen Temmerman<sup>50</sup>, Anna
- 16 Thorson<sup>2</sup>, Soe Soe Thwin<sup>2</sup>, Jorge E. Tolosa<sup>49, 51, 52</sup>, Julia Townson<sup>44</sup>, Miguel Valencia-Prado<sup>53</sup>,
- 17 Silvia Visentin<sup>14</sup>, Peter von Dadelszen<sup>32, 54</sup>, Kristina Adams Waldorf<sup>30, 31</sup>, Clare Whitehead<sup>55</sup>,
- Huixia Yang<sup>56</sup>, Kristian Thorlund<sup>57</sup>, and James M. Tielsch<sup>1</sup>
- 20 1 Department of Global Health, George Washington University Milken Institute School of
- Public Health, Washington, DC, USA
- 22 Department of Sexual and Reproductive Health and Research, World Health Organization,
- 23 Geneva, Switzerland

24 Division of Maternal Fetal Medicine, University of California Los Angeles, Los Angeles, CA, 25 **United States** 26 Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Sciences 27 Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA 28 US Centers for Disease Control and Prevention, Kisumu, Kenya 29 30 Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy 31 32 Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and 33 Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 34 35 Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain. 36 37 10 School of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain 11 Departmento de Obstetricia y Ginecologia, Clinica Alemana de Santiago, Facultad de 38 39 Medicina Clinica Alemana-Universidad del Desarrollo, Santiago, Chile 40 12 Biostatistics Center, The George Washington University, Washington, DC, USA 41 13 OBGYN, The International Federation of Gynecology and Obstetrics, London, United 42 Kingdom 43 14 Department of Woman's and Child's Health, Obstetrics and Gynecologic Clinic, University of

Padua, Padua, Italy

45 15 Surveillance for Emerging Threats to Mothers and Babies, Puerto Rico Department of 46 Health, San Juan, Puerto Rico 16 Asian Research and Training Institute for Skill Transfer (ARTIST), Bengaluru, India 47 17 Center for Vaccine Development and Global Health, University of Maryland, School of 48 49 Medicine, Baltimore, MD, USA 50 18 Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University 51 Hospital, Lausanne, Switzerland 52 19 Department of Pediatrics, University of California San Francisco, CA, San Francisco, USA 53 20 Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, 54 United Kingdom 55 21 Global Health Research, FHI 360, Durham, NC, USA 56 22 Gynecology and Obstetrics, Felix Bulnes Hospital and RedSalud Clinic, Santiago, Chile 57 23 Kenya Medical Research Institute-Center for Global Health Research, Kisumu Kenya 58 24 National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University 59 of Oxford, Oxford, United Kingdom 25 Department of Women and Child Health, Women Health Area, Fondazione Policlinico 60 Universitario Agostino Gemelli, IRCCS, Rome, Italy 61 26 Catholic University of Sacred Hearth, Rome, Italy 62 63 27 Medical Research Council / Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda 64 28 Pediatric Infectious Diseases Research Group, St. George's University of London, United 65 66 Kingdom

29 Department of Metabolism, Digestion, and Reproduction, Imperial College London, United 67 68 Kingdom 30 Department of Obstetrics and Gynecology, School of Medicine, University of Washington, 69 USA 70 71 31 Department of Global Health, School of Public Health, University of Washington, 72 Washington, USA 73 32 Department of Women and Children's Health, School of Life Course Sciences, King's 74 College London, United Kingdom 75 33 Institute of Women and Children's Health, King's College Hospital, London, UK 76 34 Clinical Research Division, National Institute of Perinatology, Mexico City, Mexico 77 35 ABC Medical Center, Fetal Surgery Clinic, Mexico City, Mexico 78 36 Division of Statistics and Epidemiology, RTI International, NC, USA 79 37 University of Utah Health, USA 38 Department of Obstetrics and Gynecology, The University of British Columbia, Vancouver, 80 81 Canada 39 Department of Epidemiology and Center for Global Health, University of Pittsburgh 82 Graduate School of Public Health, Pittsburgh, PA, USA 83 84 40 Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, 85 Cape Town, South Africa 41 Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of 86 Public Health, Baltimore, MD, USA 87 42 Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland 88

89 43 Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne 90 Switzerland 44 Center for Trials Research, Cardiff University, Wales, United Kingdom 91 45 Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong 92 93 Kong 46 Pediatric Growth and Nutrition Branch, National Institute of Health, Bethesda, MD, USA 94 95 47 Federation International Federation Gynaecology & Obstetrics, Imperial College London United Kingdom 96 97 48 PeriCovid (PREPARE) - Uganda Team, Makerere University - Johns Hopkins University 98 Research Collaboration, Uganda 99 49 Maternal Fetal Unit. Universidad Pontificia Bolivariana. RECOGEST Study. Colombia. 100 50 Department of Obstetrics and Gynecology, Aga Khan University, Nairobi, Kenya 101 51 Department of Obstetrics and Gynecology, Maternal Fetal Medicine, Oregon Health and 102 Science University, Portland, OR, USA 103 52 St. Luke's University Health Network, Department of Obstetrics & Gynecology, Maternal 104 Fetal Medicine, Bethlehem, PA, USA 105 53 Children with Special Medical Needs Division, Puerto Rico Department of Health, San Juan, 106 Puerto Rico 107 54 Global Health Institute, King's College London, United Kingdom 55 Department of Maternal Fetal Medicine, University of Melbourne, Royal Women's Hospital, 108 Parkville, VIC, Australia 109 56 Health Science Center, Peking University, Beijing, China 110

57 Department of Health Research Methods Evidence and Impact, McMaster University,
Hamilton, ON, Canada
\*Corresponding Author:
Email: EmilySmith@gwu.edu (ES)

## **Abstract**

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

We urgently need answers to basic epidemiological questions regarding SARS-CoV-2 infection in pregnant and postpartum women and its effect on their newborns. While many national registries, health facilities, and research groups are collecting relevant data, we need a collaborative and methodologically rigorous approach to better combine these data and address knowledge gaps, especially those related to rare outcomes. We propose that using a sequential. prospective meta-analysis (PMA) is the best approach to generate data for policy- and practiceoriented guidelines. As the pandemic evolves, additional studies identified retrospectively by the steering committee or through living systematic reviews will be invited to participate in this PMA. Investigators can contribute to the PMA by either submitting individual patient data or running standardized code to generate aggregate data estimates. For the primary analysis, we will pool data using two-stage meta-analysis methods. The meta-analyses will be updated as additional data accrue in each contributing study and as additional studies meet study-specific time or data accrual thresholds for sharing. At the time of publication, investigators of 25 studies, including more than 76,000 pregnancies, in 41 countries had agreed to share data for this analysis. Among the included studies, 12 have a contemporaneous comparison group of pregnancies without COVID-19, and four studies include a comparison group of non-pregnant women of reproductive age with COVID-19. Protocols and updates will be maintained publicly. Results will be shared with key stakeholders, including the World Health Organization (WHO) Maternal, Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Data contributors will share results with local stakeholders. Scientific publications will be published in open-access journals on an ongoing basis.

## Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to over 244 million confirmed cases of coronavirus disease 2019 (COVID-19) and claimed more than 4.9 million lives globally, as of October 2021 [1], and these are likely underestimates [2]. The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) note that pregnant women may be at higher risk of developing severe illness due to COVID-19 [3,4]. The specific mechanisms for this increased risk are unknown, though may be related to physiologic and immunologic changes during pregnancy. Pregnant women are generally at increased risk for severe illness from many infectious diseases including influenza, hepatitis E, malaria, and herpes simplex virus [5]. Additionally, other coronaviruses such as severe acute respiratory syndrome (SARS) are thought to pose higher risks for adverse outcomes to pregnant people; although there is only a single case-control study comparing 10 pregnant to 40 non-pregnant SARS patients [6,7].

Pregnant women with COVID-19, and their offspring, may be at increased risk for complications due to severe illness and adverse pregnancy outcomes. A living systematic review suggests that pregnant women with COVID-19, compared to non-pregnant women with COVID-19, are more than twice as likely to be admitted to an intensive care unit (ICU) or require invasive ventilation [8]. In an observational cohort study of 1,219 pregnant women across 33 U.S. hospitals with positive SARS-CoV-2 test (molecular or antigen) at the time of delivery, severe or critical COVID-19 was associated with a 40% increase in hypertensive disorders of pregnancy and a 42% increase in preterm birth, as compared to asymptomatic pregnant patients [9]. A multi-national case-control study (INTERCOVID) including 706 pregnant women with COVID-19 and 1,424 pregnant women without COVID-19 found that COVID-19 diagnosis was associated with increased risk of preeclampsia and eclampsia, severe infections, intensive care unit (ICU) admission and death [10]. A pooled analysis of 41 studies including 3323

pregnant women with COVID-19 found that one-third of their newborns were admitted to the neonatal intensive care unit (NICU); a meta-analysis of ten studies found that newborns born to pregnant women with COVID-19 were nearly five times more likely to be admitted to the NICU as compared to COVID-19 negative pregnancies [8]. Reports of mother-to-child transmission of SARS-CoV-2 during the antepartum, intrapartum, or early postnatal period remain limited.

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

Despite the urgent need to accurately document the number of cases, severe illness, and deaths in pregnant women, available data on maternal and infant complications related to COVID-19 remain heterogenous [11]. The high degree of heterogeneity in study designs, comparison groups, and definitions of key health outcomes across studies makes it difficult to clearly understand any excess risks and guide policy for pregnant and postpartum women and their newborns. For example, the current (February 2021) living systematic review on COVID-19 in pregnancy included 192 studies with 64,676 pregnant and postpartum patients; the heterogeneity in published outcomes meant that only a small fraction of those studies could be combined for key analyses, and data from some regions of the world, (e.g., sub-Saharan Africa) were absent. For example, data were available from only a handful of studies to examine a few risk factors for a single outcome (severe COVID and death), and there were fewer than 10 studies that compared the risk of maternal, fetal, and newborn outcomes between pregnant and postpartum patients versus either pregnant patients without COVID-19 or nonpregnant women of reproductive age with COVID-19 [8]. Further, we have limited data on the efficacy of treatments and preventives in pregnancy and postpartum, due largely to the systematic exclusions of pregnant people from the relevant clinical trials until recently. The same was true of the seminal vaccine trials, although vaccine studies among pregnant women began in early 2021 (ClinicalTrials.gov Identifier: NCT04754594) [12]. Establishing mother-to-child transmission of SARS-CoV-2 has also been challenging because consensus was lacking on case definition for intrauterine, intrapartum or early postpartum transmission of SARS-CoV-2

until February 2021 [13], and all proposed definitions have required clinicians and researchers to follow specific testing protocols [14–18].

COVID-19 data in pregnancy and infancy was scarce at first, and now it is heterogeneous. These shortcomings exist in part because data collection protocols have differed, and the underlying population risks for severe illnesses vary globally. It is therefore necessary to generate high-quality information with a unified data harmonization plan and analytic strategy. This approach will permit us to make evidence-driven decisions and to create guidelines for the prevention and treatment of COVID-19 in pregnant women. Because little of the existing data can be pooled, our ability to make strong recommendations related to COVID-19's risks in pregnancy and the postpartum period is limited. We are similarly constrained in our capacity to offer guidance as to the potential benefits of new interventions, like vaccines. So we propose to fill this gap by conducting a sequential prospective meta-analysis (PMA). This PMA will be a robust, collaborative, global approach to accrue harmonized data, with the objective of generating policy and practice-relevant data about the epidemiology of COVID-19 in the pregnancy and postnatal periods.

#### **Methods**

The protocol for this serial prospective meta-analysis was registered with PROSPERO (ID: 188955) on May 28, 2020. A prospective meta-analysis identifies studies that will contribute data to the meta-analysis, as well as establishes the analysis plans, before the results of the individual studies are known [19]. This approach is similar to a multi-site registry or cohort in the sense that studies work to harmonize collection of key outcomes, but differs from multi-site studies in that each site implements a study design and local protocol that is appropriate for

their context [19]. Our goal is to provide a maximally flexible, robust, collaborative, and inclusive analysis framework that is methodologically appropriate.

#### **Ethical Approval**

All individual study sites will obtain appropriate ethical approval for their independent data collection activities. As this project is a meta-analysis using aggregate study estimates or analyses of secondary, de-identified individual patient data, it is not classified as human research and thus is exempt from IRB approval.

#### Language

Not all those who are pregnant or give birth identify as women. We use the terms "pregnant women" and "pregnant people" throughout. This accurately reflects both study designs (e.g. a comparison group including those who self-report as women between the ages to 15 and 45) and the language used by the studies contributing data.

#### **Research Questions**

The study aims to answer basic epidemiological questions about COVID-19 and its impact on maternal and newborn health by pooling data from independent studies using harmonized data definitions and an individual patient data meta-analytic framework to minimize data variability.

Analyses will be performed in three groups. First, we will provide descriptive statistics among pregnant women with COVID-19. To understand the relative risks associated with COVID-19 in pregnancy, we will compare pregnant people with COVID-19 to i) other pregnant people without COVID-19 and ii) non-pregnant women of reproductive age (15-45 years) with confirmed or suspected COVID-19.

Specific objectives regarding COVID-19 among pregnant or postpartum women include: i) describe the natural history of COVID-19; ii) estimate the incidence of and risk factors for hospitalization, admission to intensive care unit, receipt of critical care, and use of invasive ventilation (for COVID-19); and iii) estimate the infection and case fatality rate. For each of these outcomes, we will also compare the risk for pregnant women with COVID-19 to non-pregnant women of reproductive age with confirmed or suspected COVID-19.

Specific objectives regarding maternal health among pregnant or postpartum women with COVID-19 are to estimate the incidence or prevalence of: i) maternal morbidities including hypertensive disorders of pregnancy, abnormal placentation, preterm prelabor rupture of membranes, hemorrhage, embolic disease, etc.; ii) maternal and pregnancy-related death; iii) adverse pregnancy outcomes including stillbirth, preterm birth, small-for-gestational age birth, and low birthweight. For each of these outcomes, we will also compare the risk for pregnant women with COVID-19 to other pregnant women without COVID-19.

Specific objectives regarding newborn health among newborns born to patients with COVID-19 are to estimate the incidence and timing of and risk factors for: i) congenital anomalies; ii) perinatal and (early) neonatal mortality; and iii) intrauterine, intrapartum, or early peripartum transmission of SARS-CoV-2 from mother to child. When appropriate, we will compare these risks to those of newborns born to women without COVID-19 during pregnancy.

Specific objectives regarding SARS-CoV-2 in biospecimens (e.g. nasopharyngeal, vaginal, or rectal swab, maternal blood, pregnancy tissue, placenta, amniotic fluid, cord blood, breast milk) include estimating: i) the proportion of biospecimens with detectable SARS-CoV-2 virus and median viral load; ii) the association between virus or viral load in biospecimen and key outcomes described above.

#### Search strategy & study inclusion

We originally recruited study sites to join the proposed prospective meta-analysis first via professional research networks, and subsequently via key stakeholder networks. Stakeholders at the National Institute of Child Health and Human Development (NICHD) at the U.S. National Institutes of Health (NIH) supported recruitment of NIH-funded maternal and child health network groups and other U.S. government funded projects. Stakeholders at the World Health Organization (WHO) in the Departments of Maternal, Newborn, Child, and Adolescent Health (MNCAH) and of Sexual and Reproductive Health and Research (SRH) supported recruitment of researchers engaged in the COVID-19 MNCAH research network and the SRH pregnancy cohorts working group [20]. Stakeholders from the International Federation of Gynecology and Obstetrics (FIGO) supported recruitment by issuing an invitation through their international network. Studies were invited to participate based solely on study design. Eligible study designs included: i) registries enrolling all suspected or confirmed cases in pregnancy or postpartum period, ii) cohorts enrolling all pregnant women, or iii) case-control studies enrolling pregnant or postpartum women with suspected or confirmed COVID-19. There were no a priori sample size limitations due to the dynamic epidemiology of the pandemic. Study investigators confirmed their intent to contribute to the PMA via a letter of intent or signing a collaboration agreement.

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

Building on concepts laid out in the Framework for Adaptive Meta-analyses (FAME) [21], we will also collaborate with the PregCOV-19 Living Systematic Review Consortium to identify studies that might be eligible for post-publication inclusion into the proposed meta-analysis. The search strategy for the LSR was previously published [8,22]. We will screen all published studies included in the living systematic review for potential inclusion in the PMA using the following criteria: i) the study conforms to the study designs outlined above; ii) there is a defined catchment area (e.g., certain hospitals, states, etc.); and iii) the sample size included at least 25 pregnant or postpartum people with confirmed or suspected COVID-19 who were consecutively recruited or identified through surveillance.

#### **Exposure (Suspected or Confirmed SARS-CoV-2 Infection)**

Cov-2 infection via a nucleic acid amplification test, regardless of clinical signs or symptoms. The original protocol was expanded to include COVID-19 cases confirmed via antigen tests as they became validated and widely used over the course of the pandemic. Suspected cases will be defined according to the WHO August 7, 2020 case definition based on either a) clinical (acute onset fever and cough, or acute onset of three or more pre-identified signs and symptoms) and epidemiological criteria (residing, working, or traveling in an area with high risk of transmission or community transmission in the past 14 days or working in any health care setting) or the severe acute respiratory illness (SARI) case definition [23]. Probable COVID-19 infections will also be defined according to the WHO August 7, 2020 case definition (clinical criteria and contact with a case; a suspected case with chest imaging, recent anosmia or ageusia onset without other cause, respiratory disease preceding death and contact with a case) [23].

**Outcomes of Interest** 

309

310

311

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

Outcomes related to women's health will include:

- Mortality: all-cause mortality, COVID-19 specific mortality, and pregnancy-related and maternal mortality;
  - COVID-19 related clinical signs and symptoms: fever, cough, shortness of breath, dizziness or fainting, body aches, runny nose, sore throat, loss of sense of smell, loss of sense of taste, sneezing, fatigue, nausea, vomiting, diarrhea, and headache;
  - Morbidity and healthcare utilization related to COVID-19 severity: pneumonia diagnosis, hospitalization, admittance to an intensive care unit (ICU), or use of critical care interventions;
  - Pregnancy-related morbidities: hypertensive disorders of pregnancy including gestational hypertension, preeclampsia, eclampsia, hyperemesis gravidarum, fetal growth restriction, abnormal placentation (placenta previa and placenta accreta spectrum), placental abruption, preterm labor, preterm prelabor rupture of membranes, hemorrhage (antepartum/intrapartum; postpartum; abortion-related), embolic disease, or anesthetic complications. We also collected data on cesarean delivery.
  - Adverse pregnancy outcomes: stillbirth (fetal death ≥28 weeks' gestation per WHO definition), early preterm birth (<34 weeks gestation), preterm birth (<37 weeks gestation), small-for-gestational-age birth (<3rd and <10th percentile per the INTERGROWTH-21<sup>st</sup> newborn reference values) [24], short-for-gestational-age birth (<3rd and <10th percentile per the INTERGROWTH-21<sup>st</sup> newborn reference values on length [25], low birthweight (<2500 grams), and very low birthweight (<1500 grams).</p>
  - Presence of SARS-CoV-2 and viral load in maternal biological specimens including:
     amniotic fluid, placenta (maternal or fetal side), cord blood, vaginal swab, feces or rectal

swab, nasopharyngeal swab, pregnancy tissue (fetus or pregnancy sac and placenta) in the case of stillbirth or abortion, breastmilk, and maternal blood.

#### Neonatal outcomes of interest include:

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

- Congenital anomalies: neural tube defects, microcephaly, congenital malformations of ear, congenital heart defects, orofacial clefts, congenital malformations of digestive system, congenital malformations of genital organs, abdominal wall defects, chromosomal abnormalities, reduction defects of upper and lower limbs, or talipes equinovarus (clubfoot);
- Early neonatal (<7 days) and neonatal (<28 days) death;
- Perinatal death (stillbirth (>28 weeks) or early neonatal death (<7 days);
- Admission to and length of stay in neonatal intensive care unit (NICU);
- Mother-to-child transmission of SARS-CoV-2 (differentiating intrauterine versus intrapartum or early peripartum infection if possible).

## **Data Harmonization**

We developed the draft data modules and questions in April 2020 based on a proposed set of questions from the Pregnancy CoRonavIrus Outcomes RegIsTrY (PRIORITY) study (ClinicalTrials.gov Identifier: NCT04323839). We also reviewed and included questions from the case report and data collection forms developed by the Department of Sexual and Reproductive Health (SRH), HRP, WHO and the WHE, WHO prospective cohort study, and the U.S. Centers for Disease Control and Prevention (CDC) Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET) study [26,27]. We requested two rounds of feedback via a survey and by email from the >50 participants of the bi-monthly informal meeting established at the

beginning of the pandemic called the "Perinatal COVID-19 Global Gathering". The current data modules reflect feedback and general consensus among survey respondents. The final draft of the data modules and core variables was finalized and shared broadly on June 2, 2020 (S File 1). We updated the data modules in September 2020 to reflect evolving understanding of SARS-CoV-2 infection in newborns and to reflect the updated SRH, HRP, WHE UNITY generic protocol developed by WHO for COVID-19-related pregnancy cohort studies [26] (S File 2).

## **Data Sharing & Study-Specific Data Analysis**

We will develop a codebook and statistical codes for each contributing study to map original study variables to the PMA core variables. Investigators can join the PMA either by submitting individual patient data or running standardized code to generate aggregate data estimates that can be included in the meta-analysis. The same data quality and consistency checks will be performed for each study, and any issues will be resolved with study investigators. Studies will be eligible to contribute data to the PMA when they have accrued at least 25 confirmed cases with completed follow up.

Study-specific estimates for the two-stage meta-analysis will be produced using standardized analytical codes, and aggregated measures will be exported into a database for the meta-analyses. Individual studies are expected to proceed with their own study publications and can use any analyses generated by the PMA for publication or policy making in their study context.

#### **Overlapping Data**

For each updated meta-analysis, we will review included studies for potentially overlapping participants to avoid including individual participants in the estimates for more than one study. We will choose a single study to contribute cases from given locations (e.g. health facilities, cities, states, or countries). The study with the most complete data will be selected to contribute, or in the case of similar data between studies, we will include data from the study that was the first to join the PMA. The number of studies and the number of cases per study is therefore likely to change with each updated meta-analysis, given this robust analytical strategy. We will use a modified version of the Newcastle Ottawa Scale to assess the risk of bias of individual studies.

#### **Methods for Data Synthesis**

Ideally, all individual-level data would be combined for one-stage meta-analysis. However, we anticipate that the ability to quickly share data and the degree of willingness to share individual patient data may vary by country and across collaborators and institutions. Thus, we will plan for a step-wise statistical analysis plan where the most feasible and simple analyses (that contribute directly to our research questions) are prioritized, and more advanced statistical modelling will be conducted subsequently.

For the first stage of analysis, prevalence, and incidence data for the respective outcomes, overall and by risk factor, will be pooled using the conventional DerSimonian-Laird random-effects model [28]. For analyses where only proportions or crude incidence rates are used, the Arcsine method may be applied to stabilize the statistics and ensure approximate asymptotic normality [29]. For analyses comparing pregnant COVID-19 cases to a) COVID-19 negative pregnancies or b) non-pregnant women with COVID, we will calculate the relative risk or odds ratio (for case-control studies) for each outcome; effect estimates will be pooled using

the conventional DerSimonian-Laird random-effects model [28]. We will assess forest plots visually for heterogeneity. When at least ten studies are being pooled, we will also quantify heterogeneity by the  $l^2$  statistic [30].

#### **Analysis of Subgroups**

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

Where appropriate and as sample size allows, we will consider meta-regression or subgroup analyses by the following study level characteristics: study design and sampling strategy, proportion of confirmed COVID-19 cases (out of suspected and confirmed cases). national maternal mortality ratio, national neonatal mortality rate, and geographic region. We will also consider subgroup analysis by the following individual patient characteristics to identify risk factors or effect modifiers for specific outcomes: confirmed versus suspected COVID-19 case status; gestational age at COVID-19 onset (by week or by trimester), COVID-19 severity, prepregnancy health conditions or comorbidities [diabetes, hypertension, cardiovascular disease, obesity (Body Mass Index >30 kg/m<sup>2</sup>), underweight (Body Mass Index <18.5 kg/m<sup>2</sup>), tuberculosis, malaria, HIV/AIDS, syphilis, anemia (hemoglobin < 11 g/dL)], maternal morbidities (also described above as outcomes), maternal vaccination status (influenza, COVID-19), calendar time or time since first COVID-19 diagnosis in the study area, parity, maternal age, race or ethnicity, and maternal education. Some of these risk factors may be considered both outcomes of having COVID-19 in pregnancy or factors that exacerbate SARS-CoV-2 infection in pregnancy; we will attempt to disambiguate between the two based on the timing of diagnoses whenever possible.

#### Sample size considerations

Consistent with the GRADE event-based approach, we will avoid "very low precision" by requiring a minimum number of three sites or a total of 100 events for each outcome to run the first analysis [31]. As data accumulate, we will evaluate the robustness of the inferences and whether the answer can be reasonably inferred via a conservative sample size. Assuming at least 50% heterogeneity between sites, the need for 90% power and 5% type 1 error to detect a difference, a conservative 1% prevalence/incidence and a risk ratio of 1.5 for the considered subgroup, a minimum of 30,000 participants are required to demonstrate an effect for each outcome and the proposed subgroups (risk factors). Alternatively, a total of 400 events or more may be used as a threshold for 'sufficient evidence' in accordance with recommendation of the GRADEPROfiler [31,32]. When these thresholds are met, the steering committee must decide whether additional, updated meta-analyses will be performed.

#### Governance

The steering committee will consist of at least one member from each participating site, key stakeholders (S File 3), and the technical coordinating team at the George Washington University. When a formal vote is needed, the following teams will each cast one official vote: each group of investigators linked to participating studies, each key stakeholder organization, and the technical coordinating team. The steering committee will prioritize research questions and agree on common elements of data collection. They will disseminate results, including rapid reports to key stakeholders, webinars, and submission of manuscripts to preprint servers and scientific journals. The technical coordinating team will develop protocols for data transfer and ensure data quality; write the statistical analysis plans; and conduct meta-analyses.

# **Participating studies**

At the time of publication, 25 studies (in 41 countries) were actively participating in the ongoing PMA (Table 1). Among these studies, 11 have a contemporaneous comparison group of pregnancies without COVID-19; two studies include a comparison group of non-pregnant women of reproductive age. The median anticipated sample size of participating studies is 1,500.

More than 76,000 pregnancies

in total are expected to contribute to the completed meta-analyses (Table 1). These studies include data from 41 countries: Argentina, Australia, Bangladesh, Belgium, Brazil, Canada, Chile, China, Colombia, Democratic Republic of the Congo, Egypt, France, French Guyana, The Gambia, Germany, Ghana, Guatemala, Hong Kong, India, Israel, Italy, Kenya, Lebanon, Mali, Mexico, Mozambique, Netherlands, New Zealand, Nigeria, Pakistan, Peru, Portugal, Puerto Rico, Rwanda, South Africa, Spain, Sweden, Switzerland, Turkey, Uganda, United Kingdom, United States, and Zambia (Fig 1). Data from additional countries is expected from the WHO prospective cohort study and other studies that will be identified via the published literature. A description of each study, including the study investigators and institutional affiliations, study design description, recruitment methods, anticipated sample sizes, recruitment timeline, and primary outcomes are presented in supplementary tables (S3 File).

#### Table 1. Characteristics of participating studies

Study	Country of Study	Anticipated Sample Size (Pregnant Women)	Pregnant COVID-19 Case Recruitment Strategies							
			Universal COVID- 19 Screening		COVID-19 Care			Comparison Group		
			Labor & Delivery	Antenatal Care	Hospitalized for COVID	Outpatient Care for COVID-19	Testing Site (Symptoms or Exposure)	None	Non-COVID- 19 Pregnancies	Non- pregnant COVID-19 cases
AFREHealth	Multiple <sup>1</sup>	350		•	X	•			X	X
ANCOV Kenya	Kenya	2500	Х	X		Х	Х		Х	
ARTIST India	India	300	Х	X			Х	Х		
CanCOVID-Preg	Canada	6000	Mixed		Х	Х	Х		X	Х
Cerner Real World Data	USA	5000	Mixed						Χ	
China/Hong Kong	China, Hong Kong	146	X	•	Х		X	Х		
CHOPAN Australia	Australia, New Zealand	50						х		
COVI-Preg	Multiple <sup>2</sup>	1700	X		Х	Х	Х		X	
Gestacovid Chile	Chile	1500	X	Χ	Х	Х	Х	Х		
Madrid Registry	Spain	200	X	X			X	Х		
Mali ANC + Surveillance	Mali	3000		Χ		Х	Χ		Χ	
Mali ANC Case-Control	Mali	1500		Χ					Χ	
Mexico National Registry	Mexico	11031	Х		Х					Х
NICHD Global Network	Multiple <sup>3</sup>	20,000	Random	Sample					Χ	
NICHD MFMU Network	United States	14,000	Most	X	X	X	X		Χ	•
PANCOVID	Multiple <sup>4</sup>	8263	Х		X	Х		Х		
PERICOVID (PRECISE)	Multiple <sup>5</sup>	6000		X					Χ	X
PERICOVID (PREPARE)	Multiple <sup>6</sup>	400	Х	Х	Х	X	X		X	

PRIORITY USA	United States	1500	X	Х	X	Χ	Х	X
Puerto Rico CASSS	Puerto Rico	458	Х			Х	Х	X
RECOGEST Colombia	Colombia	500			Х		Х	X
Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome	Italy	230	X		Х	X		X
UKOSS	United Kingdom	7000	Х		Х		Х	X
Washington State COVID- 19 in Pregnancy Collaborative	USA	240	X <sup>7</sup>		Х	Х	Х	X
WHO Prospective Cohorts	Multiple <sup>8</sup>	>16,000	Х	X	X	X	X	X

<sup>1</sup> Democratic Republic of the Congo, Ghana, Kenya, Nigeria, South Africa, and Uganda

- 470 2 USA, Canada, Mexico, Colombia, French Guyana, Peru, Brazil, Argentina, Chile, Australia, Rwanda, Lebanon, Israel, China, Portugal, Spain, France, Italy,
- 471 United Kingdom, Switzerland, Germany, Belgium, Netherlands, Ireland, and Egypt
- 472 3 India, Pakistan, Bangladesh, Kenya, DRC, Zambia, and Guatemala
- 473 4 United Kingdom, Albania, Argentina, Austria, Chile, China, Czech Republic, Egypt, Greece, Hong Kong, Indonesia, India, Italy
- 474 5 The Gambia, Mozambique, and Kenya
- 475 6 Uganda, Malawi
- 476 7 Universal testing prior to labor & delivery admission was not uniform across all participating clinical sites, but occurred in the majority by May of 2020. The remaining hospitals initiated universal testing for scheduled delivery admissions only.
- 8 The generic protocol for the WHO prospective cohort study is available for countries at: https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2. The final list of participating countries that will
- contribute to the meta-analysis is being confirmed.

#### Fig 1. Map of participating study sites

481

# **Discussion**

Our sequential, prospective meta-analysis aims to pool individual patient data from ongoing or completed studies, registries, and surveillance programs that identify SARS-CoV-2 infections in pregnancy and postpartum.

There are several benefits to our approach, which is guided by the principles of flexibility, robustness, collaboration, and inclusion. Early efforts to plan for pooling can reduce research waste (e.g., incompatible data, duplication of efforts) and improve the collective value of data [33]. Through collaboration since April 2020, including participation in WHO-coordinated working groups, we have developed and shared data collection tools and standardized some data collection components while several participating studies were starting their respective research. Ongoing pooling has also highlighted where data elements are missing or sparse across studies, thus providing justification for additional effort from study investigators to retrospectively extract additional data or modify their data collection forms. Further, this collaborative approach of pooling data highlights the possibility of generating robust answers to questions of collective importance at a global scale [34,35]. We are also more likely to elucidate risks related to rare outcomes. Collaboration is especially important for achieving scientific consensus regarding special populations—such as pregnant patients and newborns—who may not be specifically considered in national surveillance programs and may be actively excluded from other clinical research.

Our approach uses statistical methods for individual patient data meta-analysis, which is generally considered to be the gold standard in pooling data given the many steps used to ensure quality and consistency of the data and analyses. All data will be reviewed with the same data quality assessments, and outliers will be assessed consistently across studies. Analysis definitions will be standardized across studies. This is especially important given that for many

outcomes, study definitions vary between countries (e.g. whether a woman should receive critical care, the gestational age cutoff for defining stillbirth). Furthermore, we will avoid duplicate case counting by working with and reanalyzing data from studies that include overlapping health facilities and centers that contribute to two or more studies. This has been a major issue in COVID-19-related meta-analyses because much scientific literature is based on case reports or case series; the same cases sometimes appear in multiple published papers. Traditional meta-analyses based on the published literature cannot resolve these methodological issues.

Importantly, this approach is robust, flexible and collaborative. Each set of investigators can implement their own protocol, offering more flexibility to design a study specific to a given setting. Investigators can also proceed with their own study publications, thus ensuring an opportunity to be explicit about the local context in which the data collection took place and clearly take the credit associated with authorship. Our basic analyses will be done as a two-stage meta-analysis, allowing us flexibility in how data is shared. Studies that are willing and able can share their individual patient data directly with the data coordinating team for central analysis. Alternatively, studies that are unwilling or unable to share individual patient data can appoint their own study-specific data analyst to join the PMA data coordinating team. This approach to a "distributed" individual patient data meta-analysis meets data sharing needs for different groups, and hopefully ensures that anyone can participate. Finally, our regular steering committee meeting allows for joint decision-making about which analyses should be prioritized and when to move forward with publications. We hope to be responsive to emerging, policy-relevant questions, such as the safety and efficacy of vaccination in pregnancy.

## **Conclusion**

Prospective meta-analyses offer a rigorous way to generate definitive answers to emerging questions. In the current context of the COVID-19 pandemic, there is limited high-quality data that can be pooled in order to inform public health guidance and healthcare strategies, specifically for pregnant women and their newborns. The proposed study will contribute necessary information for evidence-based decision-making related to COVID-19 and maternal and neonatal health.

#### **Author Contributions**

ES, EO, SH, JMT were involved in the conceptualization and methodology; ES, EO were responsible for data curation; ES, VF, YA were responsible for funding acquisition; ES led investigation and writing the original draft manuscript; EO, SH contributed to the writing – original draft preparation; ES, EO conducted the analysis; EO, RZ contributed to visualization; ES, JMT provided supervision. EO, SH, RZ, KF, LM, and GWG contributed to project administration. All authors contributed to writing – review & editing.

## References

- 1 Johns Hopkins University. COVID-19 map-Johns Hopkins Coronavirus Resource Center. 2020.https://coronavirus.jhu.edu/map.html
- The true death toll of COVID-19: estimating global excess mortality.

  https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-

- mortality (accessed 26 Jul 2021).
- 555 3 CDC. Coronavirus Disease 2019 (COVID-19). 2020.https://www.cdc.gov/coronavirus/2019-556 ncov/need-extra-precautions/people-with-medical-conditions.html (accessed 16 Sep 2020).
- 557 4 (hq) WH. COVID-19 Clinical management: living guidance.
- 558 2021.https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (accessed 26 Jul 2021).
- 560 5 Sappenfield E, Jamieson DJ, Kourtis AP. Pregnancy and susceptibility to infectious diseases. *Infect Dis Obstet Gynecol* 2013;**2013**:752852.
- Lam CM, Wong SF, Leung TN, *et al.* A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. *BJOG* 2004;**111**:771–4.
- Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from Coronavirus 2019 nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other
   Human Coronavirus Infections. *Virus*es 2020;**12**:194.
- Allotey J, Stallings E, Bonet M, *et al.* Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;:m3320. doi:10.1136/bmj.m3320
- Metz TD, Clifton RG, Hughes BL, et al. Disease Severity and Perinatal Outcomes of
   Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol
   2021;137:571–80.
- 574 10 Villar J, Ariff S, Gunier RB, *et al.* Maternal and Neonatal Morbidity and Mortality Among 575 Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational 576 Cohort Study. *JAMA Pediatr* Published Online First: 22 April 2021. 577 doi:10.1001/jamapediatrics.2021.1050
- 578 11 Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age with 579 Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 580 22-June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:769–75.
- Farrell R, Michie M, Pope R. Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials. *J Empir Res Hum Res Ethics* 2020;**42**:17–23.
- 584 13 Sexual and Reproductive Health and Research. Definition and categorization of the timing 585 of mother-to-child transmission of SARS-CoV-2. 586 2021.https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-587 transmission-2021.1 (accessed 2 Sep 2021).
- 588 14 Kimberlin DW, Stagno S. Can SARS-CoV-2 Infection Be Acquired In Utero?: More Definitive Evidence Is Needed. *JAMA* 2020;**323**:1788–9.
- 590 15 Mahyuddin AP, Kanneganti A, Wong JLJ, *et al.* Mechanisms and evidence of vertical 591 transmission of infections in pregnancy including SARS-CoV-2. *Prenat Diagn* Published 592 Online First:

593 2020.https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/pd.5765?casa\_token=7xnIU0uz zAgAAAAA:IIT283\_cYNKnvzUvkGQ0iMhbS9R0HJkLnu640BWid2pQGWPorHSyel\_VRhBx 594 595 J1UaNt9LitF-PDUCPQ 596 16 Carosso A, Cosma S, Serafini P, et al. How to reduce the potential risk of vertical transmission of SARS-CoV-2 during vaginal delivery? Eur J Obstet Gynecol Reprod Biol 597 598 2020;**250**:246–9. 599 17 Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women 600 admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 2020;369:m2107. 601 602 18 Liu W, Wang J, Li W, et al. Clinical characteristics of 19 neonates born to mothers with 603 COVID-19. Front Med 2020;**14**:193–8. 19 Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of 604 605 Interventions. John Wiley & Sons 2019. 20 Maternal, Newborn, Child and Adolescent health, Ageing and COVID-19. 606 https://www.who.int/teams/maternal-newborn-child-adolescent-health-and-ageing/covid-19 607 608 (accessed 26 Jul 2021). 21 Tierney J, Vale CL, Burdett S, et al. Timely and reliable evaluation of the effects of 609 610 interventions: a framework for adaptive meta-analysis (FAME). Trials 2017;18:132–3. 611 22 Yap M, Debenham L, Kew T, et al. Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and 612 613 postpartum: a living systematic review protocol. BMJ Open 2020;10:e041868. 23 Definitions C. WHO COVID-19: Case Definitions. 614 615 24 Papageorghiou AT, Ohuma EO, Altman DG, et al. International standards for fetal growth 616 based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. *Lancet* 2014;**384**:869–79. 617

- Villar J, Ismail LC, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet* 2014;**384**:857–68.
- A prospective cohort study investigating maternal, pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-2. World Health Organization 2020. https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2 (accessed 26 Jul 2021).
- CDC. Investigating the Impact of COVID-19 during Pregnancy.
   2021.https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html (accessed 26 Jul 2021).
- 629 28 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;**7**:177–88.
- Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. *Stat Med* 2008;**27**:746–63.

632 30 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;**21**:1539-58. 633 634 31 Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing Summary of 635 Findings tables and evidence profiles—continuous outcomes. Journal of Clinical Epidemiology. 2013;66:173-83. doi:10.1016/j.jclinepi.2012.08.001 636 637 32 Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the guality of evidence—imprecision. J Clin Epidemiol 2011;64:1283-93. 638 33 Seidler AL, Hunter KE, Cheyne S, et al. A guide to prospective meta-analysis. BMJ 639 2019;**367**:l5342. 640 641 34 Smith ER, Flaherman VJ. Why you should share your data during a pandemic. BMJ Glob Health 2021; 6. doi:10.1136/bmjgh-2021-004940 642 35 Petkova E, Antman EM, Troxel AB. Pooling Data From Individual Clinical Trials in the 643 644 COVID-19 Era. *JAMA* 2020;**324**:543–5. 645 646 **Supporting information** 647 S1 File. Data modules and core variables - version June 2, 2020 648 649 S2 File. Data modules and core variables - version November 8, 2020 650 S3 File. Description of participating studies and key stakeholders 651 652 653

